Warburg-Backed Hong Kong Firm That Uses AI for Drug Discovery Files for U.S. IPO
(Bloomberg) -- Insilico Medicine, a Hong Kong-based company that uses artificial intelligence to drive drug discovery, filed confidentially for a U.S. initial public offering last week, according to people familiar with the matter.
The Warburg Pincus-backed firm is working with advisers on the first-time share sale and is looking to raise around $300 million, the people said, asking not to be identified because the matter is private.
Insilico was considering seeking a U.S. listing as soon as later this year, Bloomberg News reported in July.
Deliberations are ongoing and the company could decide not to go ahead with the IPO, the people said. Insilico didn't immediately respond to calls or emails seeking comment.
Chinese companies have all but disappeared from the list of IPO candidates on U.S. exchanges, following a crackdown on overseas listings by Beijing that wiped about $1 trillion off the aggregate market value of its listed firms. Even Hong Kong companies have faced detailed queries from the Securities and Exchange Commission. A proposed listing by billionaire Richard Li's FWD Group Holdings Ltd. is stalled as it awaits regulator approval, Bloomberg News reported in October.
LianBio, a biotechnology company with U.S. owners that does business primarily in China, priced its $325 million IPO last week, indicating that some companies may still be acceptable to regulators. Its shares fell 14% during their first day of trading Tuesday.
Founded in 2014, Insilico works with pharmaceutical and biotechnology companies and uses artificial intelligence to help improve their research and therapeutics and materials discovery, according to its website.
The firm's technology has helped generate drug candidates and complete pre-clinical studies to treat a pulmonary disease. Its partners include U.S. pharma giants Pfizer Inc. and Johnson & Johnson, and Japanese drugmakers Astellas Pharma Inc. and Taisho Pharmaceutical Holdings Co.
In addition to Warburg Pincus, Insilico also counts Qiming Venture Partners, Baidu Ventures, OrbiMed, Mirae Asset Capital and Sequoia Capital China as backers.
©2021 Bloomberg L.P.
With assistance from Bloomberg
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
